Trupanion Receives a Buy from RBC CapitalBy Ryan Adsit
According to TipRanks.com, Bruckner is a 2-star analyst with an average return of -0.6% and a 33.3% success rate. Bruckner covers the Technology sector, focusing on stocks such as Quotient Technology Inc, Rubicon Technology, and Rubicon Project.
Currently, the analyst consensus on Trupanion is Moderate Buy and the average price target is $19, representing a 27.2% upside.
In a report issued on November 1, Canaccord Genuity also reiterated a Buy rating on the stock with a $19 price target.
Based on Trupanion’s latest earnings report from March 31, the company posted quarterly revenue of $42.72M and quarterly net profit of -$2.57M. In comparison, last year the company earned revenue of $37.86M and had a net profit of -$4.64M.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock.
Trupanion, Inc. operates as a direct-to-consumer monthly subscription service provider. It provides medical insurance plans for cats and dogs throughout the United States, Canada and Puerto Rico. The company operates its business through two segments: Subscription and Others. The Subscription segment engages in the business of monthly subscriptions of medical plans. The Others segment includes the writing of policies for an unaffiliated managing general agent and policies written under a federal government program. Trupanion was founded by Darryl Rawlings in January 2000 and is headquartered in Seattle, WA.